No description available.

Introducción: La enfermedad renal crónica es un problema de salud a nivel mundial. Se estima que muchos pacientes los cuales inician el tratamiento presentan un alto índice de mortalidad y de poca adherencia en los primeros días del tratamiento; sin embargo, son pocos los estudios que investigan sobre el nivel de adherencia presente en aquellos pacientes que llevan este tratamiento, lo cual conlleva a que no exista un estándar para medir el mismo. Objetivo: Identificar la frecuencia de los factores relacionados a la no adherencia al tratamiento de hemodiálisis presentes en pacientes con enfermedad renal crónica. Materiales y Métodos: Se realizó un estudio descriptivo y de corte transversal con un muestreo no probabilístico. Se definió como pacientes no adherentes aquellos que presentaran como mínimo 1 falta a sus sesiones o aquellos que disminuyeron la duración de la sesión por un tiempo mayor igual a 10 minutos. Resultados: Fueron 30 los pacientes catalogados como no adherentes, un 73% fue de sexo masculino, además, la etiología más reportada en estos pacientes fue la diabetes mellitus. Dentro de los factores de no adherencia, los más destacados fueron los familiares, así como los institucionales. Conclusiones: Se encontró que el porcentaje de pacientes no adherentes se encontraba dentro del rango reportado por otros estudios; asimismo tuvieron una edad media de 45 años siendo la mayoría de sexo masculino. / Introduction: Chronic kidney disease is a global health problem. It is estimated that patients that begin dialysis have a higher rate of mortality and low adherence in the first days of the treatment. Objective: Identify the frequency of the factors related to poor adherence to hemodialysis present in patients with chronic kidney disease. Materials and methods: A descriptive study with transversal cut and a non-probabilistic sampling. Patients were defined as non adherent if they had one or more skipped sessions during the month or if they shortened their sessions for a period of time of 10 or more minutes. Results: Patients defined as non adherent were 30, 73% were males, diabetes mellitus was the etiology most reported among these patients. Observing factors of no adherence, family and institutional factors were the most relevant in the evaluated patients Conclusions: We found the percentage of non adherent patients was in the range according to other researches made, also the mid range age was of 45 being the most males.

La presente revisión crítica titulada “Complicaciones clínicas más frecuentes en los pacientes durante el tratamiento de hemodiálisis” es una investigación secundaria que utilizó la metodología Enfermería Basada en Evidencia, tuvo como objetivo identificar las complicaciones clínicas más frecuentes que presentan los pacientes durante el tratamiento de hemodiálisis con Enfermedad Renal Crónica. Formulándose la pregunta clínica con esquema de PS: ¿Cuáles son las complicaciones clínicas más frecuentes en los pacientes durante el tratamiento de hemodiálisis? La búsqueda de estudios fué desde mayo hasta octubre 2017 en adelante, es decir con 5 años de antigüedad en diversos idiomas, inglés, portugués y se empleó base de datos (Redib.org, repositorio, Researghgate, Esprints repositorio, Pubmed, Scielo, Proquest.). Se seleccionó 11 investigaciones, sometidos a la lista de Guía de Validez y utilidad aparentes de Gálvez Toro, pasando solo una. Se usó las listas chequeo de Bobenrieth Astete, de acuerdo a la metodología del artículo, para valorar la calidad metodológica, se obtuvo nivel de evidencia III de recomendación A. Se encontró como respuesta ante la pregunta, que los pacientes sometidos a la terapia de hemodiálisis presentarán hipotensión arterial, siendo esta la complicación clínica más frecuente durante la sesión de hemodiálisis. Además, manifestaran otros síntomas como calambres, vómitos, dolor de cabeza, mareos, arritmia, náuseas, convulsiones, diarrea, sudoración, debilidad, dificultad para respirar, dolores corporales y temblores, las cuales deben ser observadas porque según su intensidad afectará la calidad de vida de los pacientes. / The present critical review entitled “Most frequent clinical complications in patients during hemodialysis treatment” is a secondary investigation that used the Evidence-Based Nursing methodology, its objective was to identify the most frequent clinical complications that patients present during hemodialysis treatment. with Chronic Kidney Disease. Formulating the clinical question with PS scheme: What are the most frequent clinical complications in patients during hemodialysis treatment? The search for studies was from May to October 2017 onwards, that is, 5 years old in various languages, English, Portuguese, and a database was used (Redib.org, repository, Researghgate, Esprints repository, Pubmed, Scielo, Proquest.)11 investigations were selected, submitted to the list of Gálvez Toro's Guide to Apparent Validity and Usefulness, passing only one. The Bobenrieth Astete checklists were used, according to the methodology of the article, to assess the methodological quality, level of evidence III of recommendation A was obtained. It was found in response to the question that patients undergoing hemodialysis therapy will present arterial hypotension, this being the most frequent clinical complication during the hemodialysis session. In addition, they will manifest other symptoms such as cramps, vomiting, headache, dizziness, arrhythmia, nausea, convulsions, diarrhea, sweating, weakness, difficulty breathing, body pains and tremors, which must be observed because depending on their intensity it will affect the quality of patients' lives.

Thesis (MScMedSc)--Stellenbosch University, 2012. / ENGLISH ABSTRACT: The purpose of this study was to investigate the association of the selected MYH9 single nucleotide polymorphisms (SNPs) with chronic kidney disease (CKD) and its related co-morbidities in the South African mixed ancestry population residing in Bellville South, Cape Town. In 2008, two landmark studies identified SNPs in the MYH9 gene which explained most of the increased risk for non-diabetic CKD in African Americans. These polymorphisms were later found to be weakly associated with diabetic nephropathy. Three SNPs that exhibited independent evidence for association with CKD were selected (rs5756152, rs4821480 and rs12107). These were genotyped using a Taqman genotyping assay on a BioRad MiniOpticon and confirmed by sequencing in 724 subjects from Bellville South, Cape Town, South Africa. Prevalent CKD was defined based on the estimated glomerular filtration rate calculated using the modification of diet in renal disease (MDRD) formula. Chronic kidney disease was present in 214 subjects (29.6%), 96.3% were stage 3 and only 8 subjects were stage 4. In additive allelic models, adjusted for age and gender, rs5756152 demonstrated an association with kidney function whereby each G allele of rs5756152 increased eGFR by 3.67 ml/min/1.73, reduced serum creatinine by 4.5% and increased fasting plasma glucose by 0.51 mmol/L. When an interaction model was used, the effect of rs5756152 on serum creatinine, eGFR and blood glucose levels was retained, and enhanced, but only in diabetic subjects. In addition, rs4821480 T allele increased eGFR while rs12107 A allele decreased glucose levels in diabetic subjects. In contrast to reports that MYH9 SNPs are strongly associated with non-diabetic end stage renal disease, our study demonstrated that rs5756152 and rs4821480 are associated with early kidney function derangements in type 2 diabetes whilst rs12107 is associated with glucose metabolism. Our findings, along with previous reports, suggest that the MYH9 gene may have a broader genetic risk effect on different types of kidney diseases than previously thought. / AFRIKAANSE OPSOMMING: Hierdie studie het ondersoek ingestel na die verband tussen drie gekose MYH9-enkelnukleotied-polimorfismes (SNP’s) en chroniese niersiekte (hierna ‘niersiekte’), wat verwante ko-morbiditeite insluit, onder ’n Suid-Afrikaanse populasie van gemengde afkoms in Bellville-Suid, Kaapstad. Twee rigpuntstudies het in 2008 op SNP’s in die MYH9-geen afgekom wat verklaar het waarom Afro-Amerikaners ’n hoër risiko vir niediabetiese niersiekte toon. Later is bevind dat hierdie polimorfismes ook ’n swak verband met diabetiese nefropatie het. Drie SNP’s wat elk onafhanklik bewys gelewer het van ’n verband met niersiekte is vervolgens gekies (rs5756152, rs4821480 en rs12107). Die SNP’s is daarná met behulp van die Taqman-toets op ’n BioRad MiniOpticon aan genotipering onderwerp, en is toe deur middel van reeksbepaling by 724 proefpersone van Bellville-Suid, Kaapstad, Suid-Afrika, bevestig. Die voorkoms van niersiekte is bepaal op grond van die geraamde glomerulêre filtrasietempo (eGFR), wat aan die hand van die ‘niersiekte-dieetveranderings’- (MDRD-)formule bereken is. Daar is bevind dat 214 proefpersone (29,6%) aan chroniese niersiekte ly – 96,3% was in fase 3 en slegs agt proefpersone in fase 4. In toegevoegde alleliese modelle wat vir ouderdom en geslag aangepas is, het rs5756152 ’n verband met nierfunksie getoon: Elke G-allel van rs5756152 het eGFR met 3,67 ml/min/1,73 verhoog, serumkreatinien met 4,5% verlaag en vastende plasmaglukose met 0,51 mmol/L verhoog. Toe ’n interaksiemodel gebruik is, is die effek van rs5756152 op serumkreatinien, eGFR en bloedglukosevlakke behou en versterk, hoewel slegs by diabetiese proefpersone. Daarbenewens het die T-allel van rs4821480 eGFR verhoog, terwyl die A-allel van rs12107 ook glukosevlakke by diabetiese proefpersone verlaag het. In teenstelling met bewerings dat MYH9-SNP’s ’n sterk verband met niediabetiese eindstadiumniersiekte toon, het hierdie studie bewys dat rs5756152 en rs4821480 met vroeë nierfunksieversteurings by tipe 2-diabetes verband hou, terwyl rs12107 weer met glukosemetabolisme verbind word. Tesame met vorige studies, doen hierdie navorsingsbevindinge dus aan die hand dat die MYH9-geen dalk ’n groter genetiese risiko-effek op verskillende tipes niersiekte het as wat voorheen vermoed is. / Cape Peninsula University of Technology Research Fund / University of Stellenbosch Merit Bursary

The progressively increasing prevalence of the Metabolic Syndrome (MetS) has emerged as a major global health concern since the MetS is associated with an increased risk for cardiovascular morbidity and mortality. Central obesity represents a key feature of the MetS and is strongly related to all MetS comorbidities. Dysregulation of adipose tissue-derived proteins, so called adipokines, has been implied to partially contribute to these effects. Recently, fibroblast growth factor-21 (FGF-21) has been introduced as a novel insulin sensitizing and weight reducing adipokine with potential therapeutic properties. However, data on FGF-21 elimination are rather limited. Therefore, FGF-21 regulation in relation to renal function has been investigated in a patient population with chronic kidney disease (CKD, study population 1), as well as one with acute kidney impairment (study population 2). In study population 1 (n = 499), patients were distributed into five CKD subgroups according to estimated glomerular filtration rate (eGFR). Median FGF-21 serum concentrations progressively increased from CKD stage 1 to stage 5 and highest values of FGF-21 were detected in stage 5 (1: 86.4 ng/l; 2: 206.4 ng/l; 3: 289.8 ng/l; 4: 591.3 ng/l; 5: 1918.1 ng/l). Furthermore, eGFR remained the strongest predictor for FGF-21 levels in multivariate analysis. For study population 2 (n = 32), blood samples were obtained before elective unilateral partial or total nephrectomy, as well as within 30 hours after surgery. In this population FGF-21 levels significantly increased after surgery (325.0 ng/l) as compared to before surgery (255.5 ng/l). Furthermore, relative changes of FGF-21 were independently and positively predicted by relative changes of creatinine in this cohort. These results are in accordance with the hypothesis that FGF-21 is eliminated by the kidneys and that the extent of kidney dysfunction substantially contributes to serum FGF-21 levels. However, additional animal experiments and prospective clinical studies are needed to further elucidate the role of the kidneys in FGF-21 physiology.

Patients with chronic kidney disease are at higher risk of developing cardiovascular disease. The complex, interaction between the kidney and the cardiovascular system is incompletely understood, particularly at the early stages of the cardiovascular continuum. The overall aim of this thesis was to clarify novel aspects of the interplay between the kidney and the cardiovascular system at different stages of the cardiovascular continuum; from risk factors such as insulin resistance, inflammation and oxidative stress, via sub-clinical cardiovascular damage such as endothelial dysfunction and left ventricular dysfunction, to overt cardiovascular death. This thesis is based on two community-based cohorts of elderly, Uppsala Longitudinal Study of Adult Men (ULSAM) and Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS). The first study, show that higher insulin sensitivity, measured with euglycemic-hyperinsulinemic clamp technique was associated to improve estimated glomerular filtration rate (eGFR) in participants with normal fasting plasma glucose, normal glucose tolerance and normal eGFR. In longitudinal analyses, higher insulin sensitivity at baseline was associated with lower risk of impaired renal function during follow-up. In the second study, eGFR was inversely associated with different inflammatory markers (C-reactive protein, interleukin-6, serum amyloid A) and positively associated with a marker of oxidative stress (urinary F2-isoprostanes). In line with this, the urinary albumin/creatinine ratio was positively associated with these inflammatory markers, and negatively associated with oxidative stress. In study three, higher eGFR was associated with better endothelial function as assessed by the invasive forearm model. Further, in study four, higher eGFR was significantly associated with higher left ventricular systolic function (ejection fraction). The 5th study of the thesis shows that higher urinary albumin excretion rate (UAER) and lower eGFR was independently associated with an increased risk for cardiovascular mortality. Analyses of global model fit, discrimination, calibration, and reclassification suggest that UAER and eGFR add relevant prognostic information beyond established cardiovascular risk factors in participants without prevalent cardiovascular disease. Conclusion: this thesis show that the interaction between the kidney and the cardiovascular system plays an important role in the development of cardiovascular disease and that this interplay begins at an early asymptomatic stage of the disease process.

Cardiovascular disease (CVD) and erectile dysfunction (ED) have common etiologies, such as increased adiposity and chronic diseases. Incident ED is known to be a sentinel of CVD, providing a unique opportunity for early lifestyle interventions to attenuate the progression of disease. The internal pudendal artery (IPA) plays an important role in controlling resistance to penile blood flow and thereby erections. Although morphological and functional disturbances in the IPA have been associated with ED, few studies have characterized changes in the IPA as it relates to increased adiposity and chronic diseases (e.g., chronic kidney disease [CKD]). Finally, although both vascular calcification and ED have been shown to be prevalent in patients with CKD, there has yet to be an assessment of associated mechanisms. The effect of lifestyle modifications on erectile function was evaluated in both experimental and clinical settings. Specifically, the studies assessed the effect of caloric restriction (CR) in rats and of chronic exercise in sedentary, overweight or obese male and female subjects. In rats, structural and functional changes of the IPA and erectile responses were characterized in relation to increasing adiposity and to CKD. Experimentally, the susceptibility of various vascular beds to calcification in CKD was determined. Clinically, erectile and female sexual function was assessed in patients with Stage 3 to 5 CKD, who had no history of CVD. In rats, CR blunted the accumulation of abdominal adiposity, and attenuated progression of both endothelial dysfunction and ED, independently of morphological changes in the IPA. Rats with CKD had an increased frequency of ED, greater endothelial dysfunction, and altered vascular morphology, yet vascular calcification per se did not account for ED. In the clinical study, sedentary and overweight or obese males with ED, but not females, had a significantly higher body mass index (BMI) and waist circumference. Chronic exercise significantly improved ED and female sexual dysfunction (FSD). Clinically, CKD was associated with ED and FSD as well as increased coronary artery calcification and endothelial dysfunction. These findings support the concept that early detection of cardiovascular abnormalities, using incident ED as a sentinel, should facilitate early interventions in otherwise asymptomatic populations. / Thesis (Ph.D, Pharmacology & Toxicology) -- Queen's University, 2013-09-30 22:33:20.436

A growing number of factors, including costs, technological advancements, ageing populations, and medical errors, are leading industrialized countries to invest in research on alternative solutions to improve their health-care systems and increase patients’ quality of life. Personal health systems (PHS) examplify the use of information and communication technologies that enable a paradigm shift from the traditional hospital-centered healthcare delivery model toward a preventive and person-centered approach. PHS offer the means to monitor a patient’s health using wearable, portable or implantable systems that offer ubiquitous, unobtrusive biodata acquisition, allowing remote monitoring of treatment and access to the patient’s status. Electrical bioimpedance (EBI) technology is non-invasive, quick and relatively affordable technique that can be used for assessing and monitoring different health conditions, e.g., body composition assessments for nutrition. When combined with state-of-the-art advances in sensors and textiles, EBI technologies are fostering the implementation of wearable bioimpedance monitors that use functional garments for personalized healthcare applications. This research work is focused on the development of wearable EBI-based monitoring systems for ubiquitous health monitoring applications. The monitoring systems are built upon portable monitoring instrumentation and custom-made textile electrode garments. Portable EBI-based monitors have been developed using the latest material technology and advances in system-on-chip technology. For instance, a portable EBI spectrometer has been validated against a commercial spectrometer for total body composition assessment using functional textile electrode garments. The development of wearable EBI-based monitoring units using functional garments and dry textile electrodes for body composition assessment and respiratory monitoring has been shown to be a feasible approach. The availability of these measurement systems indicates progress toward the real implementation of personalized healthcare systems. / <p>QC 20170517</p>

L'administration chronique de rHuEPO peut engendrer de graves effets secondaires. Une augmentation de l’hématocrite provoquée par la rHuEPO, en augmentant l'érythrocytose, la viscosité sanguine et les forces de cisaillement à la surface vasculaire, peut être responsable d'hypertension artérielle (HTA) et de thromboses artérielles. La présence d'une fonction endothéliale normale et de monoxyde d'azote (NO) peut contrer les effets délétères thrombogène et hypertenseur de l'EPO. Sur ces bases, nous avons étudié les effets cardiovasculaires d'une administration chronique de rHuEPO dans différentes situations : dans le cadre du dopage, chezdes rats "sportifs" présentant une dysfonction endothéliale NO-dépendante induite par l'administration chronique de L-NAME et dans le cadre d'un traitement chez des rats urémiques développant une dysfonction endothéliale NO-dépendante résultante d'une néphrectomie de 5/6de la masse rénale. Chez nos rats entrainés, dopés et traités au L-NAME, nous avons observé une altération de la performance physique avec une mortalité importante (51%). Une HTA sévères'est développée chez ces rats, avec des valeurs de pression artérielle (> 220 mmHg) bien plusélevées que celles des rats recevant le L-NAME seul, associée à une altération de la vasorelaxation NO-dépendante aortique (< 60%). Les rats insuffisants rénaux (IRC) ont eux aussi montré une augmentation de la pression artérielle et une dysfonction endothéliale en réponse àl'acétylcholine au niveau de l'aorte et en réponse à une élévation du flux au niveau de l'artère mésentérique perfusée. Ces différents paramètres ont été améliorés par l'exercice. Les coupes de rein colorées au rouge Sirius ont montré une fibrose accentuée chez les rats CKD. La fibrose, la créatinémie et l'albuminurie ont été diminuées par l'exercice seul mais ont été aggravées chez les rats du groupe CKD+EPO+Ex. L'activité NADPH oxydase et l'expression des Nox4, p67phox etMAPK erk1/2 ont été augmentées chez les les rats CKD. L'exercice ou la rHuEPO ont prévenuces augmentations. Cependant, l'activité de la NAD(P)H oxydase et l’expression des MAPKerk1/2 sont restées élevées dans le rein des rats CKD+EPO+Ex. Nos données suggèrent que l'exercice seul a un effet protecteur contre les dysfonctions vasculaire et rénale et la fibrose rénale. Ces effets protecteurs sont associés à une inhibition de l'activité de la NADPH oxydase et des voies de signalisation MAPK erk1/2. Par contre, l'exercice combiné avec le traitement rHuEPO, a des effets délétères sur la structure et la fonction rénale des rats CKD. Ces effets nocifs semblent liés à la stimulation de la NADPH oxydase et des voies de signalisation MAPKerk1/2. Malgré les effets protecteurs cardiovasculaire et rénal de l'entraînement physique, ces résultats mettent en évidence que la fonction rénale peut être potentiellement endommagée ainsique la structure du rein en combinant l'exercice avec le traitement rHuEPO dans l'insuffisance rénale. En conclusion, nous pouvons dire que la rHuEPO affecte gravement la fonction cardiovasculaire du rat entraîné présentant une dysfonction endothéliale. Ce risque étant fatal,beaucoup de sportifs, voulant augmenter leur performance, mettent leur vie en danger. Par ailleurs, ayant remarqué les effets délétères au niveau rénal, en associant exercice et traitement rHuEPO dans des conditions expérimentales sur un modèle d'insuffisance rénale, nous suggérons une investigation clinique afin de vérifier la transposition de nos résultats aux patients insuffisants rénaux. / The chronic administration of rHuEPO can engender side effects. An increase of the hematocritinduced by rHuEPO, by increasing the erythrocytosis, the blood viscosity and the shear stress onvascular surface, can be responsible of arterial high blood pressure and arterial thrombosis. Thepresence of a normal endothelial function and nitric oxide (NO) can counter the noxious effectsof rHuEPO. On these bases, we studied the cardiovascular effects of a chronic administration ofrHuEPO in various frames: within doping field, to trained rats with L-NAME-induced NOdependentendothelial dysfunction and within the framework of a treatment, to chronic kidneydisease (CKD) rats developing endothelial dysfunction caused by the "5/6 nephrectomy". In ourdoped rats, we observed an important mortality (51%). A severe arterial high blood pressuredeveloped in these rats (> 220 mmHg) associated with an impairment of the NO-dependentvasorelaxation (< 60 %). CKD rats also showed an increase in blood pressure and an endothelialdysfunction, in response to acetylcholine in the aorta and in response to a rise in flow in perfusedmesenteric artery. These parameters were improved by exercise. Kidney sections stained withSirius red showed marked fibrosis in CKD rats. Fibrosis, creatinine and albumin were decreasedby exercise alone but were increased in rats from the CKD + EPO + Ex group. NAD(P)H oxidaseactivity and the expression of Nox4, p67phox, and MAPK erk1/2 were increased in CKDrats. Exercise or rHuEPO prevented these increases. However, the NAD(P)H oxidase activityand the expression of MAPK erk1/2 remained high in the kidney of rats from the CKD+EPO+Exgroup. Our data suggest that exercise alone has a protective effect against vascular and renaldysfunction and renal fibrosis. These protective effects are linked to the downregulation of theNADPH oxidase activity and MAPK erk1/2 signaling pathways. However, exercise combinedwith rHuEPO treatment has deleterious effects on kidney structure and function in CKDrats. These adverse effects appear to be related to the stimulation of NADPH oxidase and MAPKerk1/2 signaling pathways. Despite the cardiovascular and renal protective effects of physicaltraining, these results highlight the potentially damaging renal function and structure bycombining exercise with rHuEPO therapy in renal failure. In conclusion, we can say that therHuEPO affects seriously cardiovascular function in trained rat with endothelial dysfunction. Thisrisk being fatal, many sportsmen, looking to increase their performance, put their life in danger.Moreover, having noticed the deleterious effects in the kidney by combining exercise andrHuEPO therapy under experimental conditions on a model of renal failure, we suggest a clinicalinvestigation to verify the transposition of our results to patients with renal failure

L'insuffisance rénale chronique (IRC) se caractérise par la diminution progressive et irréversible des fonctions renales. Elle s'accompagne d'une accumulation d'un ensemble de toxines responsable du syndrome urémique. Le syndrome urémique touche tous les organes, et de façon préoccupante le système cardiovasculaire. Il est associé à une dysfonction endothéliale, à la production d'un stress oxydant et d'une inflammation. L'objectif de cette thèse était d'identifier les mécanismes moléculaires responsables des complications du syndrome urémique. La première partie a tenté d'identifier des épissages alternatifs associés à l'IRC. Deux épissages alternatifs ont été identifiés. Cependant, le petit nombre d'épissages alternatifs trouvé au vue du nombre de gènes étudiés, nous permet de conclure que si l'IRC peut être responsable de l'apparition d'épissages alternatifs, ce phénomène n'est pas déterminant dans la régulation de l'expression des gènes responsable des complications de l'IRC. Dans la deuxième partie, nous avons montré par une étude clinique que le taux d'une toxine urémique, l'acide indole acétique (IAA), était associé à la mortalité et à la survenue d'événements cardio-vasculaires. In vitro, l'IAA induit un stress oxydant et un signal inflammatoire par l'induction de la cyclooxygénase 2 (COX-2). Une voie inflammatoire non génomique impliquant aryl hydrocarbon receptor (AhR), p38 MAPK et NF-κB est responsable de l'induction de la COX-2 endothéliale par l'IAA. Nos travaux ont identifié de nouvelles cibles thérapeutiques dont la modulation pourrait avoir un impact sur la mortalité cardiovasculaire des patients présentant une maladie rénale chronique. / Chronic kidney disease (CKD) is characterized by an irreversible decrease in kidney functions. Accumulation of uremic toxins is implicated in the uremic syndrome. Uremic syndrome affects all organs and particularly the cardiovascular system. The aim of this thesis was to identify and understand the molecular mechanisms implicated in the uremic syndrome.The first part attempted to ascertain the existence of alternative splice events associated with CKD. Two alternative splicing were identified. The small number of alternative splice events highlighted allows us to conclude that this phenomenon does not seem to be a key event in the modulation of gene expression during CKD.In the second part of this work, we demonstrated that the plasmatic concentration of an uremic toxin, Indole-3-acetic acid (IAA), is associated with all-cause mortality and major cardiovascular events. In vitro, we demonstrated that IAA induced endothelial cyclooxygenase-2 expression and endothelial oxidative stress production. IAA activated an endothelial Aryl hydrocarbon receptor/P38MAPK/NF-κB pathway. The activation of this inflammatory AHR dependant pathway could play a critical role in the increase of cardiovascular morbidity and mortality observed during CKD.Our work provides new therapeutic targets. The modulation of their activation could reduce cardiovascular mortality in patients with chronic kidney disease.